Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Penetrance of different cancer types in families with Li-Fraumeni syndrome: a validation study using multi-center cohorts.

Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha P, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W.

Cancer Res. 2019 Nov 12. pii: canres.0728.2019. doi: 10.1158/0008-5472.CAN-19-0728. [Epub ahead of print]

PMID:
31719101
2.

Who should access germline genome sequencing? A mixed methods study of patient views.

Best MC, Butow P, Jacobs C, Savard J, Biesecker B, Ballinger ML, Bartley N, Davies G, Napier CE, Smit AK, Thomas DM, Newson AJ; Members of the PiGeOn Project.

Clin Genet. 2019 Nov 1. doi: 10.1111/cge.13664. [Epub ahead of print]

PMID:
31674008
3.

Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts.

Jones RM, Melton PE, Pinese M, Rea AJ, Ingley E, Ballinger ML; International Sarcoma Kindred Study, Wood DJ, Thomas DM, Moses EK.

BMC Med Genet. 2019 May 3;20(1):69. doi: 10.1186/s12881-019-0808-9.

4.

Author Correction: Therapeutic implications of germline genetic findings in cancer.

Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML, Thomas DM.

Nat Rev Clin Oncol. 2019 Jun;16(6):397. doi: 10.1038/s41571-019-0212-6.

PMID:
30996255
5.

Diagnosis of fusion genes using targeted RNA sequencing.

Heyer EE, Deveson IW, Wooi D, Selinger CI, Lyons RJ, Hayes VM, O'Toole SA, Ballinger ML, Gill D, Thomas DM, Mercer TR, Blackburn J.

Nat Commun. 2019 Mar 27;10(1):1388. doi: 10.1038/s41467-019-09374-9.

6.

A quantitative model to predict pathogenicity of missense variants in the TP53 gene.

Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM, James PA.

Hum Mutat. 2019 Jun;40(6):788-800. doi: 10.1002/humu.23739. Epub 2019 Mar 18.

PMID:
30840781
7.

Therapeutic implications of germline genetic findings in cancer.

Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, Ballinger ML, Thomas DM.

Nat Rev Clin Oncol. 2019 Jun;16(6):386-396. doi: 10.1038/s41571-019-0179-3. Review. Erratum in: Nat Rev Clin Oncol. 2019 Apr 17;:.

PMID:
30783251
8.

Translating genomic risk into an early detection strategy for sarcoma.

Ballinger ML, Pinese M, Thomas DM.

Genes Chromosomes Cancer. 2019 Feb;58(2):130-136. doi: 10.1002/gcc.22697. Epub 2018 Nov 29. Review.

PMID:
30382615
9.

A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings.

Rasmussen V, Forrest LE, Rogasik M, Girodet M, Meeus P, Sunyach MP, Blay JY, Bally O, Brahmi M, Ballinger ML, Niedermayr E, Thomas DM, Halliday J, James P, Ray-Coquard I, Young MA; International Sarcoma Kindred Study.

Per Med. 2018 Jan;15(1):13-24. doi: 10.2217/pme-2017-0035.

PMID:
29714116
10.

The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.

Best M, Newson AJ, Meiser B, Juraskova I, Goldstein D, Tucker K, Ballinger ML, Hess D, Schlub TE, Biesecker B, Vines R, Vines K, Thomas D, Young MA, Savard J, Jacobs C, Butow P.

BMC Cancer. 2018 Apr 23;18(1):454. doi: 10.1186/s12885-018-4366-x.

11.

The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling.

Best M, Newson AJ, Meiser B, Juraskova I, Goldstein D, Tucker K, Ballinger ML, Hess D, Schlub TE, Biesecker B, Vines R, Vines K, Thomas D, Young MA, Savard J, Jacobs C, Butow P.

BMC Cancer. 2018 Apr 5;18(1):389. doi: 10.1186/s12885-018-4310-0.

12.

Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk.

Willis AM, Smith SK, Meiser B, Ballinger ML, Thomas DM, Tattersall M; International Sarcoma Kindred Study (ISKS); Kathleen Cuningham National Consortium for Research into Familial Breast Cancer (kConFab), Young MA.

J Genet Couns. 2018 Sep;27(5):1055-1066. doi: 10.1007/s10897-018-0223-y. Epub 2018 Feb 17.

PMID:
29455319
13.

Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.

Koster R, Panagiotou OA, Wheeler WA, Karlins E, Gastier-Foster JM, Caminada de Toledo SR, Petrilli AS, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Lecanda F, Serra M, Hattinger C, Picci P, Scotlandi K, Thomas DM, Ballinger ML, Gorlick R, Barkauskas DA, Spector LG, Tucker M, Belynda DH, Yeager M, Hoover RN, Wacholder S, Chanock SJ, Savage SA, Mirabello L.

Int J Cancer. 2018 Apr 15;142(8):1594-1601. doi: 10.1002/ijc.31195. Epub 2017 Dec 23.

14.

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppe E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA.

JAMA Oncol. 2017 Dec 1;3(12):1634-1639. doi: 10.1001/jamaoncol.2017.1968. Erratum in: JAMA Oncol. 2018 Apr 1;4(4):590.

15.

Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.

Ballinger ML, Ferris NJ, Moodie K, Mitchell G, Shanley S, James PA, Thomas DM.

JAMA Oncol. 2017 Dec 1;3(12):1735-1736. doi: 10.1001/jamaoncol.2017.1355. No abstract available.

16.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

17.

Estimating TP53 Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPRO.

Peng G, Bojadzieva J, Ballinger ML, Li J, Blackford AL, Mai PL, Savage SA, Thomas DM, Strong LC, Wang W.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):837-844. doi: 10.1158/1055-9965.EPI-16-0695. Epub 2017 Jan 30.

18.

Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

McBride KA, Ballinger ML, Schlub TE, Young MA, Tattersall MHN, Kirk J, Eeles R, Killick E, Walker LG, Shanley S, Thomas DM, Mitchell G.

Fam Cancer. 2017 Jul;16(3):423-432. doi: 10.1007/s10689-016-9964-7.

PMID:
28124295
19.

Sarcoma and germ-line DICER1 mutations - Authors' reply.

Ballinger ML, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Nov;17(11):e471. doi: 10.1016/S1470-2045(16)30527-7. No abstract available.

PMID:
27819238
20.

Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review.

Willis AM, Smith SK, Meiser B, Ballinger ML, Thomas DM, Young MA.

Clin Genet. 2017 Aug;92(2):121-133. doi: 10.1111/cge.12868. Epub 2016 Oct 23. Review.

PMID:
27643459
21.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.

PMID:
27498913
22.

Diagnosis and Management of Hereditary Sarcoma.

Thomas DM, Ballinger ML.

Recent Results Cancer Res. 2016;205:169-89. doi: 10.1007/978-3-319-29998-3_10.

PMID:
27075354
23.

International survey of awareness of genetic risk in the clinical sarcoma community.

McBride KA, Schlub TE, Ballinger ML, Thomas DM, Tattersall MH.

Asia Pac J Clin Oncol. 2016 Jun;12(2):133-42. doi: 10.1111/ajco.12457. Epub 2016 Feb 29.

PMID:
26923110
24.

A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.

Mirabello L, Koster R, Moriarity BS, Spector LG, Meltzer PS, Gary J, Machiela MJ, Pankratz N, Panagiotou OA, Largaespada D, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, de Toledo SR, Petrilli AS, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Andrulis IL, Wunder JS, Gokgoz N, Serra M, Hattinger C, Picci P, Scotlandi K, Flanagan AM, Tirabosco R, Amary MF, Halai D, Ballinger ML, Thomas DM, Davis S, Barkauskas DA, Marina N, Helman L, Otto GM, Becklin KL, Wolf NK, Weg MT, Tucker M, Wacholder S, Fraumeni JF Jr, Caporaso NE, Boland JF, Hicks BD, Vogt A, Burdett L, Yeager M, Hoover RN, Chanock SJ, Savage SA.

Cancer Discov. 2015 Sep;5(9):920-31. doi: 10.1158/2159-8290.CD-15-0125. Epub 2015 Jun 17.

25.

Clinical implications of genomics for cancer risk genetics.

Thomas DM, James PA, Ballinger ML.

Lancet Oncol. 2015 Jun;16(6):e303-8. doi: 10.1016/S1470-2045(15)70026-4. Epub 2015 May 27.

PMID:
26065615
26.

Surveillance recommendations for patients with germline TP53 mutations.

Ballinger ML, Mitchell G, Thomas DM.

Curr Opin Oncol. 2015 Jul;27(4):332-7. doi: 10.1097/CCO.0000000000000200. Review.

PMID:
26049273
27.

Timing and context: important considerations in the return of genetic results to research participants.

McBride KA, Hallowell N, Tattersall MH, Kirk J, Ballinger ML, Thomas DM, Mitchell G, Young MA.

J Community Genet. 2016 Jan;7(1):11-20. doi: 10.1007/s12687-015-0231-7. Epub 2015 May 26.

28.

Etiologic, environmental and inherited risk factors in sarcomas.

Thomas DM, Ballinger ML.

J Surg Oncol. 2015 Apr;111(5):490-5. doi: 10.1002/jso.23809. Epub 2014 Oct 21. Review.

PMID:
25335907
29.

Li-Fraumeni syndrome: cancer risk assessment and clinical management.

McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MH, Eeles RA, Thomas DM, Mitchell G.

Nat Rev Clin Oncol. 2014 May;11(5):260-71. doi: 10.1038/nrclinonc.2014.41. Epub 2014 Mar 18. Review.

PMID:
24642672
30.

High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort.

Mitchell G, Ballinger ML, Wong S, Hewitt C, James P, Young MA, Cipponi A, Pang T, Goode DL, Dobrovic A, Thomas DM; International Sarcoma Kindred Study.

PLoS One. 2013 Jul 22;8(7):e69026. doi: 10.1371/journal.pone.0069026. Print 2013.

31.

Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells.

Little PJ, Rostam MA, Piva TJ, Getachew R, Kamato D, Guidone D, Ballinger ML, Zheng W, Osman N.

J Pharm Pharmacol. 2013 Jul;65(7):1055-63. doi: 10.1111/jphp.12064. Epub 2013 Apr 24.

PMID:
23738733
32.

Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans.

Osman N, Grande-Allen KJ, Ballinger ML, Getachew R, Marasco S, O'Brien KD, Little PJ.

Cardiovasc Pathol. 2013 Mar-Apr;22(2):146-55. doi: 10.1016/j.carpath.2012.07.002. Epub 2012 Sep 21.

33.

Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFβ receptor phosphorylation.

Little PJ, Getachew R, Rezaei HB, Sanchez-Guerrero E, Khachigian LM, Wang H, Liao S, Zheng W, Ballinger ML, Osman N.

Arch Biochem Biophys. 2012 Sep 1;525(1):25-31. doi: 10.1016/j.abb.2012.05.025. Epub 2012 Jun 7.

PMID:
22683649
34.

An increased incidence of Hodgkin's lymphoma in patients with adult-onset sarcoma.

Downing ME, Dite GS, Ballinger ML; International Sarcoma Kindred Study Consortium.

Clin Sarcoma Res. 2012 Jan 9;2(1):1. doi: 10.1186/2045-3329-2-1.

35.

PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL.

Getachew R, Ballinger ML, Burch ML, Reid JJ, Khachigian LM, Wight TN, Little PJ, Osman N.

Endocrinology. 2010 Sep;151(9):4356-67. doi: 10.1210/en.2010-0027. Epub 2010 Jul 7.

PMID:
20610572
36.

Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor.

Burch ML, Ballinger ML, Yang SN, Getachew R, Itman C, Loveland K, Osman N, Little PJ.

J Biol Chem. 2010 Aug 27;285(35):26798-805. doi: 10.1074/jbc.M109.092767. Epub 2010 Jun 22.

37.

TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2.

Burch ML, Yang SN, Ballinger ML, Getachew R, Osman N, Little PJ.

Cell Mol Life Sci. 2010 Jun;67(12):2077-90. doi: 10.1007/s00018-010-0315-9. Epub 2010 Mar 7.

PMID:
20213272
38.

Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways.

Cardoso LE, Little PJ, Ballinger ML, Chan CK, Braun KR, Potter-Perigo S, Bornfeldt KE, Kinsella MG, Wight TN.

J Biol Chem. 2010 Mar 5;285(10):6987-95. doi: 10.1074/jbc.M109.088674. Epub 2009 Dec 30.

39.

Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells.

Getachew R, Ballinger ML, Burch ML, Little PJ, Osman N.

Eur J Pharmacol. 2010 Jan 25;626(2-3):186-92. doi: 10.1016/j.ejphar.2009.09.066. Epub 2009 Oct 8.

PMID:
19818754
40.

Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.

Ballinger ML, Osman N, Hashimura K, de Haan JB, Jandeleit-Dahm K, Allen T, Tannock LR, Rutledge JC, Little PJ.

J Cell Mol Med. 2010 Jun;14(6B):1408-18. doi: 10.1111/j.1582-4934.2009.00902.x. Epub 2009 Sep 14.

41.

Growth factor-mediated hyper-elongation of glycosaminoglycan chains on biglycan requires transcription and translation.

Yang SN, Burch ML, Getachew R, Ballinger ML, Osman N, Little PJ.

Arch Physiol Biochem. 2009 Jul;115(3):147-54. doi: 10.1080/13813450903110754.

PMID:
19580379
42.

Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process.

Little PJ, Ballinger ML, Burch ML, Osman N.

Open Biochem J. 2008;2:135-42. doi: 10.2174/1874091X00802010135. Epub 2008 Nov 18.

43.

Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL.

Ballinger ML, Ivey ME, Osman N, Thomas WG, Little PJ.

Atherosclerosis. 2009 Aug;205(2):451-7. doi: 10.1016/j.atherosclerosis.2009.01.024. Epub 2009 Jan 24.

PMID:
19217622
44.

p38 MAP kinase mediated proteoglycan synthesis as a target for the prevention of atherosclerosis.

Osman N, Ballinger ML, Dadlani HM, Getachew R, Burch ML, Little PJ.

Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):287-92. Review.

PMID:
19075640
45.

Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding.

Ballinger ML, Osman N, Wilks AF, Su S, Burns CJ, Bu X, Little PJ.

J Cardiovasc Pharmacol. 2008 Nov;52(5):403-12. doi: 10.1097/FJC.0b013e31818a8907.

PMID:
19033819
46.

Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis.

Little PJ, Ballinger ML, Survase S, Osman N, Ogru E, Geytenbeek S, Bruemmer D, Nigro J.

J Cardiovasc Pharmacol. 2008 Mar;51(3):274-9. doi: 10.1097/FJC.0b013e3181626ce7.

PMID:
18356692
47.

Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle.

Dadlani H, Ballinger ML, Osman N, Getachew R, Little PJ.

J Biol Chem. 2008 Mar 21;283(12):7844-52. doi: 10.1074/jbc.M703125200. Epub 2008 Jan 25.

48.

Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis.

Little PJ, Ballinger ML, Osman N.

Vasc Health Risk Manag. 2007;3(1):117-24. Review.

49.

Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease.

Grande-Allen KJ, Osman N, Ballinger ML, Dadlani H, Marasco S, Little PJ.

Cardiovasc Res. 2007 Oct 1;76(1):19-28. Epub 2007 May 17. Review.

PMID:
17560967
50.

Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents.

de Dios ST, Frontanilla KV, Nigro J, Ballinger ML, Ivey ME, Cawson EA, Little PJ.

J Diabetes Complications. 2007 Mar-Apr;21(2):108-17.

PMID:
17331859

Supplemental Content

Loading ...
Support Center